Overview

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
1. The primary objective is to study the comparative effectiveness and tolerability of boceprevir vs. telaprevir in HCV treatment, within the VA population. 2. The secondary objective: - Resource use: recording of differences in resource use, such as direct costs (e.g., drug acquisition costs) and other indirect cost (e.g., staff utilization etc.) as the study will not only derive data by comparing those two drugs but also study the effect on different treatment lengths.
Phase:
N/A
Details
Lead Sponsor:
Louis Stokes VA Medical Center
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin